Research perspectives: Future prospects for the management of metastatic triple-negative breast cancers (notice n° 504575)
[ vue normale ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 01400cam a2200181 4500500 |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20250121083956.0 |
| 041 ## - LANGUAGE CODE | |
| Language code of text/sound track or separate title | fre |
| 042 ## - AUTHENTICATION CODE | |
| Authentication code | dc |
| 100 10 - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Frenel, Jean-Sébastien |
| Relator term | author |
| 245 00 - TITLE STATEMENT | |
| Title | Research perspectives: Future prospects for the management of metastatic triple-negative breast cancers |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
| Date of publication, distribution, etc. | 2022.<br/> |
| 500 ## - GENERAL NOTE | |
| General note | 3 |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | Triple-negative breast cancer (TNBC) is a heterogeneous disease with a poor prognosis. This disease, which has long been treated solely with chemotherapy, has recently been the subject of extensive research and therapeutic progress. The success of immunotherapy and antibody-drug conjugates (ADCs) has finally opened up new perspectives for advanced and early stages of the disease. In this review, we discuss the pathways being developed to improve the effectiveness of immunotherapy with novel approaches. We also review the numerous ADCs in development and their targets. Finally, we discuss the potential role of targeted therapies, such as PI3K AKT mTOR inhibitors, and hormone therapy approaches. |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Zenatri, Morgan |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Bachelot, Thomas |
| Relator term | author |
| 786 0# - DATA SOURCE ENTRY | |
| Note | Innovations & Thérapeutiques en Oncologie | Volume 8 | Special Issue 1 | 2022-01-02 | p. 20-24 | 2431-3203 |
| 856 41 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://shs.cairn.info/journal-innovations-therapeutiques-en-oncologie-2022-HS1-page-20?lang=en&redirect-ssocas=7080">https://shs.cairn.info/journal-innovations-therapeutiques-en-oncologie-2022-HS1-page-20?lang=en&redirect-ssocas=7080</a> |
Pas d'exemplaire disponible.
Réseaux sociaux